Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NICE confirms Pradaxa recommendation

This article was originally published in Scrip

Executive Summary

Guidance published for the national health service in England and Wales confirms theNational Institute for health and Clinical Excellence's recommendation thatBoehringer Ingelheim's Pradaxa (dabigatran etexilate) be an option for the primary prevention of venous thromboembolic events in adults who have undergone elective total hip replacement surgery or elective total knee replacement surgery. The direct thrombin inhibitor was licensed by the EU in March and given a tentative NICE recommendation in July (Scrip Online, August 1st, 2008). The appraisal committee concluded that Pradaxa was as cost-effective as low-molecular weight heparin or fondaparinux, taking into account the benefits of its oral formulation. Boehringer Ingelheim says it is the first new oral anticoagulant to be launched in the UK for over 50 years.

You may also be interested in...



Cervarix link to UK girl's death "unlikely"

Local health authorities in Coventry, UK, say it is most unlikely that vaccination with GlaxoSmithKline's Cervarix (human papillomavirus vaccine) was the cause of the death of a 14-year-old schoolgirl on September 28th.

Generic Topamax launched in European markets

Patents on Janssen-Cilag's (Johnson & Johnson) anti-epileptic Topamax/Epitomax (topiramate) expired in many European countries on September 25th, and generics companies are launching their own versions quickly.

NICE confirms limits on Alimta for lung cancer

Lilly's Alimta (pemetrexed) has been recommended as a first-line treatment for some patients in England and Wales with non-small cell lung cancer (NSCLC) in binding guidance for the national health service.

Related Companies

UsernamePublicRestriction

Register

LL1121650

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel